{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:32:43Z","timestamp":1792373563869,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"U.K. Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.vaccine.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T02:48:30Z","timestamp":1472870910000},"page":"4827-4834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators"],"prefix":"10.1016","volume":"34","author":[{"given":"Rebecca P.","family":"Sumner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.08.002_b0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/02648725.1984.10647806","article-title":"Recombinant vaccinia viruses as new live vaccines","volume":"2","author":"Smith","year":"1984","journal-title":"Biotechnol Genet Eng Rev"},{"key":"10.1016\/j.vaccine.2016.08.002_b0010","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.11.79","article-title":"Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors","volume":"10","author":"Walsh","year":"2011","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.08.002_b0015","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.08.002_b0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/156652308784049363","article-title":"The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer","volume":"8","author":"Gomez","year":"2008","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2016.08.002_b0025","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.002_b0030","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0035","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2013.05.007","article-title":"Cytosolic sensing of viruses","volume":"38","author":"Goubau","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.08.002_b0040","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/JVI.02627-13","article-title":"Vaccinia virus inhibits NF-kappaB-dependent gene expression downstream of p65 translocation","volume":"88","author":"Sumner","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0045","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4161\/hv.28974","article-title":"Enhancing poxvirus vectors vaccine immunogenicity","volume":"10","author":"Garcia-Arriaza","year":"2014","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2016.08.002_b0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/imm.12422","article-title":"Enhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-kappaB inhibitor","volume":"145","author":"Ren","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2016.08.002_b0055","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1099\/vir.0.049700-0","article-title":"Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy","volume":"94","author":"Sumner","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0060","doi-asserted-by":"crossref","first-page":"e24244","DOI":"10.1371\/journal.pone.0024244","article-title":"A candidate HIV\/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses","volume":"6","author":"Garcia-Arriaza","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.002_b0065","doi-asserted-by":"crossref","first-page":"e66894","DOI":"10.1371\/journal.pone.0066894","article-title":"Improving adaptive and memory immune responses of an HIV\/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways","volume":"8","author":"Garcia-Arriaza","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.002_b0070","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1099\/vir.0.82772-0","article-title":"Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein","volume":"88","author":"Cooray","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0075","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jmb.2008.09.048","article-title":"Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3","volume":"385","author":"Kalverda","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0080","doi-asserted-by":"crossref","first-page":"e1000128","DOI":"10.1371\/journal.ppat.1000128","article-title":"Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis","volume":"4","author":"Graham","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.08.002_b0085","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1099\/0022-1317-83-8-1965","article-title":"The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence","volume":"83","author":"Bartlett","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0090","doi-asserted-by":"crossref","first-page":"e1002247","DOI":"10.1371\/journal.ppat.1002247","article-title":"Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7","volume":"7","author":"Unterholzner","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.08.002_b0095","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1099\/vir.0.052670-0","article-title":"Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection","volume":"94","author":"Benfield","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0100","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1128\/JVI.00246-12","article-title":"Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques","volume":"86","author":"Garber","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0105","doi-asserted-by":"crossref","first-page":"e12395","DOI":"10.1371\/journal.pone.0012395","article-title":"Immunogenic profiling in mice of a HIV\/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions","volume":"5","author":"Garcia-Arriaza","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.002_b0110","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/JVI.62.6.1849-1854.1988","article-title":"Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors","volume":"62","author":"Falkner","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/viro.1994.1542","article-title":"Vaccinia virus gene A36R encodes a M(r) 43\u201350K protein on the surface of extracellular enveloped virus","volume":"204","author":"Parkinson","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.08.002_b0120","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/emboj.2008.143","article-title":"Viral targeting of DEAD box protein 3 reveals its role in TBK1\/IKKepsilon-mediated IRF activation","volume":"27","author":"Schroder","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2016.08.002_b0125","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1099\/vir.0.054114-0","article-title":"Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence","volume":"94","author":"Ferguson","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0130","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1099\/0022-1317-71-11-2761","article-title":"Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route","volume":"71","author":"Williamson","year":"1990","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(92)90274-G","article-title":"A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection","volume":"71","author":"Alcami","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.08.002_b0140","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1099\/0022-1317-80-10-2751","article-title":"A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae","volume":"80","author":"Tscharke","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0145","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1099\/0022-1317-83-8-1977","article-title":"Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes","volume":"83","author":"Tscharke","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1084\/jem.20041912","article-title":"Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines","volume":"201","author":"Tscharke","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.08.002_b0155","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/JVI.00427-06","article-title":"Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice","volume":"80","author":"Tscharke","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1099\/vir.0.81417-0","article-title":"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy","volume":"87","author":"Clark","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0165","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0170","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.08.002_b0175","doi-asserted-by":"crossref","first-page":"e1002430","DOI":"10.1371\/journal.ppat.1002430","article-title":"Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence","volume":"7","author":"de Motes","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.08.002_b0180","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1099\/vir.0.80646-0","article-title":"Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara","volume":"86","author":"Staib","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0185","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1016\/j.vaccine.2011.02.023","article-title":"Deletion of the A35 gene from modified vaccinia virus ankara increases immunogenicity and isotype switching","volume":"29","author":"Rehm","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.002_b0190","doi-asserted-by":"crossref","first-page":"e32220","DOI":"10.1371\/journal.pone.0032220","article-title":"Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein","volume":"7","author":"Falivene","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.002_b0195","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/JVI.06684-11","article-title":"Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV\/AIDS vaccine candidate NYVAC-C in mice","volume":"86","author":"Gomez","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0200","doi-asserted-by":"crossref","first-page":"e74831","DOI":"10.1371\/journal.pone.0074831","article-title":"Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV\/AIDS vaccine candidate NYVAC-C","volume":"8","author":"Perdiguero","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.002_b0205","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.immuni.2013.08.034","article-title":"Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions","volume":"39","author":"Henrickson","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.08.002_b0210","doi-asserted-by":"crossref","first-page":"e1002141","DOI":"10.1371\/journal.ppat.1002141","article-title":"Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes","volume":"7","author":"Gillard","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.08.002_b0215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0952-7915(02)00354-0","article-title":"Links between innate and adaptive immunity via type I interferon","volume":"14","author":"Le Bon","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2016.08.002_b0220","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","article-title":"Regulation of effector and memory T-cell functions by type I interferon","volume":"132","author":"Huber","year":"2011","journal-title":"Immunology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16306594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16306594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T19:15:59Z","timestamp":1601061359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16306594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":44,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0264410X16306594"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}